Acorn Bioventures Files SC 13D for Q32 Bio Inc.
Ticker: QTTB · Form: SC 13D · Filed: Apr 4, 2024 · CIK: 1661998
| Field | Detail |
|---|---|
| Company | Q32 Bio Inc. (QTTB) |
| Form Type | SC 13D |
| Filed Date | Apr 4, 2024 |
| Risk Level | medium |
| Pages | 9 |
| Reading Time | 11 min |
| Key Dollar Amounts | $0.0001, $3,784,526, $1.1989, $2,655,105 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, schedule-13d, biotech
Related Tickers: Q32
TL;DR
**ACORN BUYS Q32 BIO STAKE**
AI Summary
Acorn Bioventures, L.P. has filed a Schedule 13D, indicating a change in beneficial ownership of Q32 Bio Inc. common stock. The filing, dated April 4, 2024, details Acorn Bioventures' holdings and intentions regarding the issuer. The company was formerly known as Homology Medicines, Inc. and changed its name on December 28, 2015.
Why It Matters
This filing signals a significant stakeholder's increased or changed interest in Q32 Bio Inc., potentially influencing the company's stock performance and strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings can indicate activist investor intentions or significant shifts in major holdings, which may lead to increased volatility.
Key Players & Entities
- Acorn Bioventures, L.P. (company) — Filing entity
- Q32 Bio Inc. (company) — Subject company
- Homology Medicines, Inc. (company) — Former name of Q32 Bio Inc.
- Anders Hove (person) — Contact person for Acorn Bioventures
- Adriana Schwartz, Esq. (person) — Legal counsel for Acorn Bioventures
FAQ
What is the primary purpose of this SC 13D filing?
The filing is to report a change in beneficial ownership of Q32 Bio Inc. common stock by Acorn Bioventures, L.P.
Who is the subject company of this filing?
The subject company is Q32 Bio Inc.
When was this filing submitted?
The filing was submitted on April 4, 2024.
What was Q32 Bio Inc. formerly known as?
Q32 Bio Inc. was formerly known as Homology Medicines, Inc.
Who is listed as a contact person for Acorn Bioventures, L.P. in this filing?
Anders Hove is listed as a contact person for Acorn Bioventures, L.P.
Filing Stats: 2,652 words · 11 min read · ~9 pages · Grade level 13.6 · Accepted 2024-04-04 20:33:33
Key Financial Figures
- $0.0001 — me of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securitie
- $3,784,526 — gregate purchase price of approximately $3,784,526, or approximately $1.1989 per share (th
- $1.1989 — roximately $3,784,526, or approximately $1.1989 per share (the “ Pre-Closing Fina
- $2,655,105 — of Legacy Q32’s common stock and $2,655,105 principal amount of convertible promiss
Filing Documents
- p24-1368sc13d.htm (SC 13D) — 84KB
- exhibit_99.htm (EX-99.4) — 5KB
- 0000902664-24-002747.txt ( ) — 91KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: April 4, 2024 ACORN BIOVENTURES, L.P. By: ACORN CAPITAL ADVISORS, GP, LLC, its General Partner By: /s/ Anders Hove Anders Hove, Manager ACORN CAPITAL ADVISORS, GP, LLC By: /s/ Anders Hove Anders Hove, Manager ANDERS HOVE /s/ Anders Hove